Cancer Vaccines Market Report 2026

Cancer Vaccines Market Overview

• Cancer Vaccines market size has reached to $9.36 billion in 2025 • Expected to grow to $18.2 billion in 2030 at a compound annual growth rate (CAGR) of 14.3% • Growth Driver: Government Funding Boosts Cancer Vaccines Market Growth Through Research And Development Investments • Market Trend: Quadrivalent Vaccines Gain Traction In The Cancer Vaccines Market • North America was the largest region in 2025.

What Is Covered Under Cancer Vaccines Market?

Cancer vaccines refer to cancer-treatment vaccinations and medications that aid the body in illness prevention and cancer treatment. They have the power to teach the immune system to recognize and eliminate dangerous microbes and cells. The two main types of cancer vaccines are preventive cancer vaccines and therapeutic cancer vaccines. Therapeutic vaccinations aid in the recognition of a virus or malignant cell by the immune system. The different types of cancers include prostate, cervical, colorectal, throat, and others, and involve various technologies such as dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, viral vectors, and DNA cancer vaccines. The several sectors include cancer treatment centers and research institutes.

What Is The Cancer Vaccines Market Growth Forecast?

The cancer vaccines market size is expected to see rapid growth in the next few years. It will grow to $18.2 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to advancement in vaccine platforms and delivery systems, increasing adoption of personalized cancer vaccines, expansion of clinical pipelines for therapeutic vaccines, growing government funding for cancer research, rising demand for combination cancer therapies. Major trends in the forecast period include rising development of therapeutic cancer vaccines, increasing focus on personalized and targeted immunotherapies, growing clinical trials for novel cancer vaccine technologies, expansion of preventive vaccination programs for cancer prevention, rising collaboration between pharma companies and research institutes.

Global Cancer Vaccines Market Segmentation

1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines 2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines 3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types 4) By End-User: Cancer Treatment Centers, Research Institutes Subsegments: 1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines 2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge), Talimogene Laherparepvec (T-VEC), Other Therapeutic Vaccines

What Is The Driver Of The Cancer Vaccines Market?

Increasing government funding for research and development is expected to propel the growth of the cancer vaccines market going forward. Government funding refers to money provided by a government to pay for a particular purpose. Government funding for research and development is rising to drive innovation and accelerate the development of new technologies and treatments that can address critical health and economic challenges. Cancer vaccines help government funding for research and development by creating opportunities for investment in preventive and therapeutic innovations, encouraging increased financial support for vaccine research programs. For instance, in September 2023, the National Cancer Institute, a US-based government agency, received a budget from the United States Congress of $7.3 billion in fiscal year 2023, which is a $408 million increase over 2022. Therefore, increasing government funding for research and development is driving the growth of the cancer vaccines industry.

Key Players In The Global Cancer Vaccines Market

Major companies operating in the cancer vaccines market are GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

Global Cancer Vaccines Market Trends and Insights

Major companies operating in the cancer vaccines market are increasing their focus on introducing quadrivalent vaccines to maximize revenue in the market. A quadrivalent vaccine is a type of vaccine that protects against four different strains or types of a specific virus or bacteria. For instance, in January 2023, Serum Institute of India, an India-based biotechnology company, launched CERVAVAC, the first made-in-India cervical cancer vaccine. The vaccine is designed to work on HPV types 16 and 18, as well as 6 and 11, which are responsible for at least 70% of cervical cancers. The vaccine will be administered via injection in two doses among 9–14-year-olds and three doses for those between 15 and 26.

What Are Latest Mergers And Acquisitions In The Cancer Vaccines Market?

In August 2024, NEC Bio Therapeutics, a US-based biotechnology company specializing in personalized immunotherapies, entered into a collaboration with AGC Biologics to manufacture individualized cancer vaccines. The partnership focuses on advancing NEC’s personalized neoantigen vaccine programs by leveraging AGC Biologics’ global biologics production capabilities, enabling scalable, high-quality manufacturing of bespoke cancer treatments. This collaboration aims to accelerate clinical development, enhance patient access to cutting-edge immunotherapies, and support innovation in the personalized oncology vaccine market. AGC Biologics is a US-based, leading contract development and manufacturing organization (CDMO) providing end-to-end solutions for biologics production.

Regional Insights

North America was the largest region in the cancer vaccines market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cancer Vaccines Market?

The cancer vaccines market consists of sales of Bacillus calmette-guérin, Sipuleucel-T, and Human Papillomavirus (HPV) vaccines. Values in this market are """"factory gate values,"""" that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cancer Vaccines Market Report 2026?

The cancer vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cancer vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.